The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials ...
On July 1, 2026, Vertex Pharmaceuticals announced that the FDA approved an expanded indication for CASGEVY (exagamglogene autotemcel) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results